, , 0 comments

Respiri (RSH) secures second order from mTeleHealth

  • Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing and pilot programs, which are considered the first steps towards seeking reimbursement for the device
  • mTelehealth placed a second order for additional Wheezo devices, representing revenues of around US$24,000 (around A$33,600) on top of the US$150,000 (A$210,000) order received in December 2021
  • The initiative by mTelehealth is expected to educate senior medical decision makers on the benefits of Wheezo, which is hoped to increase adoption of the device by mTelehealth customers and result in monthly subscriptions
  • Respiri is up 6.12 per cent, trading at 5.2 cents at 11:30 am AEDT

eHealth company, Respiri (RSH) has secured a second order for Wheezo from mTelehealth.

Developed in Australia, the Wheezo device analyses breath sounds for wheeze to assist patients with managing their asthma by tracking symptoms, triggers and medication use.

Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing, and pilot programs, which are considered the first steps towards seeking reimbursement for the device.

To do so, mTelehealth has placed a second order for additional Wheezo devices, representing revenues of around US$24,000 (around A$33,600) on top of the US$150,000 (A$210,000) order received in December 2021.

The initiative by mTelehealth is expected to educate senior medical decision-makers on the benefits of Wheezo, which is hoped to increase adoption of the device by mTelehealth customers and result in monthly subscriptions.

The devices are set to be air freighted immediately to key decision-makers within mTelehealth’s targeted customer base. This will enable a critical review, testing and evaluation required to expedite the piloting of Wheezo.

Respiri says these are considered the first and most difficult steps in seeking to secure reimbursement for Wheezo RPM services and inclusion of Wheezo in management protocols.

Over 600 customers have been targeted, with many of them already requesting Wheezo devices.

“Our partnership with mTelehealth has developed quickly with mTelehealth and the progress they have made with customers in only two months of customer engagement has exceeded all our expectations,” said CEO and Managing Director of Respiri, Marjan Mikel.

“This is a key step in seeking to get reimbursed Wheezo devices into the hands of patients that need it.”

Respiri was up 6.12 percent, trading at 5.2 cents at 11:30 am AEDT.